St. Jude Will Tap Heart Valve Sales Reps For VSI Initial Anastomosis Product
This article was originally published in The Gray Sheet
Executive Summary
St. Jude's strategy to capitalize long-term on its entry into the coronary artery treatment market through the $100 mil. acquisition of Vascular Science, Inc. will draw on established relationships between clinicians and the firm's Heart Valve division (cardiac surgeons) and the Daig electrophysiology division (interventionists).
You may also be interested in...
Corvascular Plans 2002 NDA Submission For Transarrest Device/Drug Combo
Corvascular is set to begin a pivotal Phase III study this year of the Transarrest drug/device combination in anticipation of an early 2002 new drug application submission for use in off-pump coronary artery bypass graft (CABG) surgery.
Corvascular Plans 2002 NDA Submission For Transarrest Device/Drug Combo
Corvascular is set to begin a pivotal Phase III study this year of the Transarrest drug/device combination in anticipation of an early 2002 new drug application submission for use in off-pump coronary artery bypass graft (CABG) surgery.
ABT IDE For "End-To-End" Anastomoses Clip Expected In Q1 2000
Advanced Bypass Technologies plans to pursue in the first quarter of 2000 an investigational device exemption to commence trials of a device for "end-to-end" sutureless anastomoses during coronary artery bypass graft surgery, the company says.